Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial.

"Conflict of interests and source of funding J. French serves as the President of the Epilepsy Study Consortium, a non-profit organization. Dr. French receives 25% salary support from the Epilepsy Study Consortium. The consortium receives funding from Supernus Pharmaceuticals Inc., as well as many other companies with AEDs in development or marketed AEDs, for work performed (principal investigator, FDA submission, consulting) by Dr. French on behalf of the Epilepsy Study Consortium. P. Baroldi, S.T. Brittain, and J.K. Johnson are current (S.T. Brittain, J.K. Johnson) or past (P. Baroldi) employees of Supernus Pharmaceuticals Inc. The PROSPER study was sponsored by Supernus Pharmaceuticals Inc."

"The authors thank Karen Malley, Malley Research Programming Inc, for statistical programming support and also Verna Ilacqua, ID&A, for editorial assistance. Funding for this study was provided by Supernus Pharmaceuticals Inc."